Sou Hu Cai Jing·2025-12-22 12:09Group 1 - The core point of the article is that Baiyunshan (00874.HK) has approved a partnership agreement for the establishment of the Guangyao Guangkai Fund, with contributions from various entities totaling RMB 1.225 billion [1] - Baiyunshan's stock closed at HKD 18.57 on December 22, 2025, reflecting a decrease of 0.38% with a trading volume of 846,000 shares and a turnover of HKD 15.673 million [1] - The company has a market capitalization of HKD 40.99 billion, ranking 5th in the Traditional Chinese Medicine II industry [1] Group 2 - The investment banks predominantly rate Baiyunshan as "Buy," with one investment bank issuing a "Buy" rating in the last 90 days [1] - The latest report from Great Wall Securities also gives Baiyunshan a "Buy" rating [1]